Sprycel: Leading the Second Generation of Tyrosine Kinase Inhibitors
Sprycel: Leading the Second Generation of Tyrosine Kinase Inhibitors
Blog Article
Emergence of Second-Generation TKIs
When imatinib became the first FDA-approved tyrosine kinase inhibitor (TKI) to treat chronic myeloid leukemia (CML) in 2001, it marked a major breakthrough in cancer treatment. However, patients developing resistance to imatinib led researchers to develop newer and more potent TKIs. Dasatinib, known chemically as dasatinib, was one such second-generation TKI that received FDA approval in 2006 for patients with CML who were resistant or intolerant to imatinib.
Wide Range of Activity Against Kinases
Sprycel was found to be a more potent inhibitor than imatinib, blocking a wider range of tyrosine kinases involved in CML and other cancers. In vitro studies showed that dasatinib inhibited the activity of Bcr-Abl, the abnormal tyrosine kinase driving CML, at levels 300 times lower than imatinib. It was also more effective against mutations conferring resistance to imatinib. Additionally, dasatinib targets SRC-family kinases associated with processes like adhesion, metastasis and angiogenesis in solid tumors. This multi-kinase inhibitory profile supported exploring Dasatinib in other cancer types beyond CML.
Promising Clinical Trial Results
Initial Phase I/II clinical trials in CML and Ph+ ALL patients found dasatinib to be highly effective in both newly diagnosed and imatinib-resistant/intolerant cases. COMPLETE, a pivotal Phase II study in imatinib-resistant/intolerant CML patients, achieved major cytogenetic responses in over 60% of patients. DASISION, a Phase III trial, demonstrated superior efficacy of dasatinib over high-dose imatinib in newly diagnosed CML patients. In lung cancer clinical trials as well, dasatinib showed encouraging anti-tumor activity both as monotherapy and in combination with chemotherapy. These robust results supported its FDA approvals for CML and Ph+ ALL.
Strong Commercial Performance
Bristol-Myers Squibb, which acquired the rights to dasatinib from Wyeth/copyright, launched Dasatinib in 2006 with a price of $70,000 per year of treatment. This was significantly higher than the competing TKIs imatinib and nilotinib. However, Dasatinib established itself as an important treatment option based on its clinical benefits in resistant and intolerant CML patients as well as its expanded label in newly diagnosed disease. Patent protection lasting until 2027 also allowed BMS to maintain Dasatinib's premium pricing. Globally, it generated over $1.7 billion in annual sales by 2010, making it one of BMS's top oncology products. Even as generics of imatinib entered the market, Dasatinib sales continued growing strong.
Broader Investigation in Other Cancers
Dasatinib demonstrated preclinical activity against breast, prostate, lung and other solid tumors and became widely investigated in clinical trials. Notable Phase III data emerged in lung cancer. In DePATO, dasatinib showed a trend toward longer survival compared to docetaxel in epidermal growth factor receptor mutant non-small cell lung cancer. The QUEST study found dasatinib was as effective as erlotinib with fewer side effects in a similar lung cancer population. Ongoing research continues exploring combinations and sequencing strategies with immune checkpoint inhibitors or targeted therapies. Trials are also evaluating dasatinib's potential to boost response rates to immunotherapy drugs. In prostate cancer, trials investigated sprycel as a radio-sensitizer as well as combining it with androgen deprivation therapy or chemotherapy.
With its original CML approvals expiring in 2022, generic competition is expected to impact Dasatinib sales moving forward. However, Bristol-Myers Squibb is actively pursuing new label expansions to maintain market share. In 2021, the FDA approved dasatinib for the first-line treatment of chronic-phase Ph+ CML in pediatric patients. In breast and other cancers as well, ongoing trials aim to define optimal patient populations where adding Dasatinib provides meaningful benefits. The multi-targeted nature of dasatinib is also being leveraged in novel drug combinations. Overall, the therapy is likely to retain an important role for many years in CML as well as specialty niche markets in other tumor types based on its unique kinase inhibition profile.
In when facing a diagnosis of chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), patients and their loved ones seek effective treatment options with manageable side effects. Enter Dasatinib, a targeted therapy designed to inhibit the abnormal proteins driving these blood cancers. By disrupting their signaling pathways, Dasatinib slows cancer cell growth and proliferation, offering patients a chance at remission and improved survival outcomes. With ongoing research and advancements, Dasatinib continues to redefine the landscape of cancer care.
Get more insights on, Sprycel
For Deeper Insights, Find the Report in the Language that You want.
French
German
Italian
Russian
Japanese
Chinese
Korean
Portuguese
About Author:
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)